Tech Company Financing Transactions

iPierian Funding Round

On 9/8/2010, iPierian received $6 million in Series B funding from Biogen Idec and SR One Capital Management.

Transaction Overview

Company Name
Announced On
9/8/2010
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Proceeds Purpose
This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
951 Gateway Blvd
South San Francisco, CA 94080
USA
Email Address
Overview
iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Profile
iPierian LinkedIn Company Profile
Social Media
iPierian Company Twitter Account
Company News
iPierian News
Facebook
iPierian on Facebook
YouTube
iPierian on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
  Nancy Stagliano LinkedIn Profile  Nancy Stagliano Twitter Account  Nancy Stagliano News  Nancy Stagliano on Facebook
VP - Bus. Development
Adam Rosenthal
  Adam Rosenthal LinkedIn Profile  Adam Rosenthal Twitter Account  Adam Rosenthal News  Adam Rosenthal on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/8/2010: TRACON Pharmaceuticals venture capital transaction
Next: 9/8/2010: Pasteuria BioScience venture capital transaction

 

Share this article

 


About Database of VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary